Home
Resources
Diseases
Compendium
Training
Evaluation
The Tool
The Tutorial
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Selected
COVID-19
Type of publications
Guidelines (1)
NITAG documentation (354)
SAGE documentation (33)
Scientific publications (4)
Systematic reviews (SYSVAC) (1089)
Regions
Africa (57)
Americas (187)
Eastern Mediterranean (10)
Europe (155)
South-East Asia (10)
Western Pacific (36)
Diseases
COVID-19 (1481)
Chikungunya (9)
Cholera (33)
Cytomegalovirus (1)
Dengue (39)
Diphtheria (79)
Ebola (16)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (66)
Hepatitis A (63)
Hepatitis B (153)
Hepatitis C (4)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (66)
HIV / AIDS (10)
Human papillomavirus (HPV) (472)
Influenza (573)
Japanese encephalitis (34)
Lyme disease, Borreliosis (1)
Malaria (27)
Measles (128)
Meningococcal disease (145)
Mpox (55)
Mumps (46)
Pertussis (104)
Pneumococcal disease (266)
Poliomyelitis (84)
Q fever (1)
Rabies (28)
Rotavirus (115)
RSV (Respiratory syncytial virus) (47)
Rubella (64)
Salmonella (2)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (59)
Tick-borne encephalitis (12)
Tuberculosis (73)
Typhoid (23)
Varicella (69)
Yellow fever (42)
Zika (1)
Show more
Methodological quality (AMSTAR 2)
High (12)
Moderate (7)
Low (111)
Critically low (685)
Not applicable (274)
1481 results found
2021
∙
Conseil Supérieur de la Santé (CSS)
Non-replicating viral vector vaccines and the Belgian COVID-19 vaccination strategy
2021
∙
NTAGI
NTAGI meeting minutes - 28 May 2021
2021
∙
JCVI
Optimising the COVID-19 vaccination programme for maximum short-term impact
2021
∙
ACIP
Overview of Janssen’s Single-Dose COVID-19 Vaccine, Ad26.COV2.S
2021
∙
Haut Conseil de la santé publique
Potential impact of the circulation of SARS-CoV-2 variants on the COVID - 19 strategy - 9 April, 2021
2021
∙
Conseil Supérieur de la Santé (CSS)
Prioritization of at-risk groups for SARS-CoV-2 Vaccination (Phase 1b)
2021
∙
Haut Conseil de la santé publique
Priority vaccination of the entourage of people immunocompromised against SARS-Cov 2 - 30 April, 2021
2021
∙
NACI
Rapid response: Updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines
2021
∙
Folkhälsomyndigheten
Recommendation for continued vaccination of priority groups
2021
∙
CoNaIn
Recommendation on the administration of additional doses for vaccination against COVID-19
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register